Genentech Seeking to Expand Tarceva into First-Line Setting in EGFR-Mutated NSCLC Patients | GenomeWeb

Originally published June 6.

By Turna Ray

CHICAGO — Roche subsidiary Genentech is in discussions with the US Food and Drug Administration about launching the non-small cell lung cancer drug Tarceva as a first-line treatment for patients with EGFR-mutated tumors. If Tarceva is launched in this indication, it will serve as an example of the use of a pharmacogenomics strategy to successfully grow a drug's market size.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.